Top

Published in:

01-02-2014 | Review Article

Prevalence and factors associated with glucocorticoids (GC) use in systemic sclerosis (SSc): a systematic review and meta-analysis of cohort studies and registries

Authors: Michele Iudici, Serena Fasano, Daniela Iacono, Barbara Russo, Giovanna Cuomo, Gabriele Valentini

Published in: Clinical Rheumatology | Issue 2/2014

Abstract

Glucocorticoids (GC) represent a mainstay in the therapeutical strategies of many autoimmune diseases, but their role in systemic sclerosis (SSc) is controversial. The main objective of this review is to assess the extent of and the factors associated with GC use in SSc patients, taking into account data from cohort studies and registries. We performed a search in MEDLINE databases updated to April 2013. The pooled prevalence and factors associated with GC utilization in both SSc patients collectively considered and in any of the two subsets of the disease were calculated. The pooled prevalence was 0.36 (95 % confidence interval (CI) 0.28–0.43) for overall sample. In six studies, data about the GC prescription in the two different subsets of the disease were available. The pooled prevalence was 0.52 (95 % CI 0.49–0.55) in diffuse and 0.33 (95 % CI 0.31–0.35) in limited cutaneous disease patients. Five papers reporting data about the dose of GC prescribed showed a pooled prevalence of 0.89 (95 % CI 0.87–0.91) for a daily dose of <15 mg of prednisone equivalent. Huge heterogeneity was identified across studies (I ² > 75 %). No significant correlation was detected between the extent of GC utilization and either the percentage of concomitant immunosuppressants intake (p = 0.347), diffuse subset (p = 0.720) or female sex (p = 0.913). Despite the limited evidence for their effectiveness, GC are frequently prescribed in SSc patients, mostly in those with the diffuse subset. The variability in the extent of their utilization in different centres is considerable and suggests the need to develop treatment recommendations.

LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, Rowell N, Wollheim F (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15:202–205PubMed

Gabrielli A, Avvedimento EV, Krieg T (2009) Scleroderma. N Engl J Med 360:1989–2003PubMedCrossRef

Spies CM, Strehl C, van der Goes MC, Bijlsma JW, Buttgereit F (2011) Glucocorticoids. Best Pract Res Clin Rheumatol 25:891–900PubMedCrossRef

Walsh LJ, Wong CA, Pringle M, Tattersfield AE (1996) Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. BMJ 10:344–346CrossRef

Fardet L, Petersen I, Nazareth I (2011) Description of oral glucocorticoid prescriptions in general population. Rev Med Interne 32:594–599 (in French)PubMedCrossRef

Overman RA, Yeh JY, Deal CL (2013) Prevalence of oral glucocorticoid usage in the United States: a general population perspective. Arthritis Care Res (Hoboken) 65:294–298CrossRef

Perez Campos D, Estevez Del Toro M, González Rojas PP, Morales Sánchez L, Gutiérrez Rojas AR (2012) Are high doses of prednisone necessary for treatment of interstitial lung disease in systemic sclerosis? Reumatol Clin 8:58–62PubMedCrossRef

Pakas I, Ioannidis JP, Malagari K, Skopouli FN, Moutsopoulos HM, Vlachoyiannopoulos PG (2002) Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease. J Rheumatol 29:298–304PubMed

Pai BS, Srinivas CR, Sabitha L, Shenoi SD, Balachandran CN, Acharya S (1995) Efficacy of dexamethasone pulse therapy in progressive systemic sclerosis. Int J Dermatol 34:726–728PubMedCrossRef

10.

Takehara K (2004) Treatment of early diffuse cutaneous systemic sclerosis patients in Japan by low-dose corticosteroids for skin involvement. Clin Exp Rheumatol 22(Suppl 33):S87–S89PubMed

11.

Sharada B, Kumar A, Kakker R, Adya CM, Pande I, Uppal SS, Pande JN, Sunderam KR, Malaviya AN (1994) Intravenous dexamethasone pulse therapy in diffuse systemic sclerosis. A randomized placebo-controlled study. Rheumatol Int 14:91–94PubMedCrossRef

12.

Iudici M, van der Goes MC, Valentini G, Bijlsma JW (2013) Glucocorticoids in systemic sclerosis: weighing up the benefits and risks—a systematic review. Clin Exp Rheumatol 2(Suppl 76):S157–S165

13.

Steen VD, Medsger TA Jr (1998) Case–control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum 41:1613–1619PubMedCrossRef

14.

Meier FM, Frommer KW, Dinser R, Walker UA, Czirjak L, Denton CP, Allanore Y, Distler O, Riemekasten G, Valentini G, Müller-Ladner U, EUSTAR Co-authors (2012) Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis 71:1355–1360PubMedCrossRef

15.

Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283:2008–2012PubMedCrossRef

16.

(1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 23:581–90.

17.

Fletcher J (2007) What is heterogeneity and is it important? BMJ 334:94–96PubMedCrossRef

18.

Sterne JA, Egger M, Smith GD (2001) Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis. BMJ 323:101–105PubMedCrossRef

19.

Hunzelmann N, Moinzadeh P, Genth E, Krieg T, Lehmacher W, Melchers I, Meurer M, Müller-Ladner U, Olski TM, Pfeiffer C, Riemekasten G, Schulze-Lohoff E, Sunderkoetter C, Weber M, German Network for Systemic Scleroderma Centers (2009) High frequency of corticosteroid and immunosuppressive therapy in patients with systemic sclerosis despite limited evidence for efficacy. Arthritis Res Ther 11:R30PubMedCentralPubMedCrossRef

20.

Mansour S, Bonner A, Muangchan C, Hudson M, Baron M, Pope JE, Canadian Scleroderma Research Group (2013) Low socioeconomic status (measured by education) and outcomes in systemic sclerosis: data from the Canadian Scleroderma Research Group. J Rheumatol 40:447–54PubMedCrossRef

21.

Nikpour M, Hissaria P, Byron J, Sahhar J, Micallef M, Paspaliaris W, Roddy J, Nash P, Sturgess A, Proudman S, Stevens W (2011) Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort. Arthritis Res Ther 13:R211PubMedCentralPubMedCrossRef

22.

Vanthuyne M, Smith V, De Langhe E, Van Praet J, Arat S, Depresseux G, Westhovens R, Blockmans D, Badot V, Cogan E, De Keyser F, Houssiau FA (2012) The Belgian Systemic Sclerosis Cohort: correlations between disease severity scores, cutaneous subsets, and autoantibody profile. J Rheumatol 39:2127–2133PubMedCrossRef

23.

Caporali R, Caccialanza R, Bonino C, Klersy C, Cereda E, Xoxi B, Crippa A, Rava ML, Orlandi M, Bonardi C, Cameletti B, Codullo V, Montecucco C (2012) Disease-related malnutrition in outpatients with systemic sclerosis. Clin Nutr 31:666–671PubMedCrossRef

24.

Hromadkova L, Soukup T, Cermakova E, Vlcek J (2012) Drug compliance in patients with systemic scleroderma. Clin Rheumatol 31:1577–1583PubMedCrossRef

25.

Foocharoen C, Mahakkanukrauh A, Suwannaroj S, Nanagara R (2011) Spontaneous skin regression and predictors of skin regression in Thai scleroderma patients. Clin Rheumatol 30:1235–1240PubMedCrossRef

26.

Fuschiotti P, Medsger TA Jr, Morel PA (2009) Effector CD8+ T cells in systemic sclerosis patients produce abnormally high levels of interleukin-13 associated with increased skin fibrosis. Arthritis Rheum 60:1119–1128PubMedCrossRef

27.

Hachulla AL, Launay D, Gaxotte V, de Groote P, Lamblin N, Devos P, Hatron PY, Beregi JP, Hachulla E (2009) Cardiac magnetic resonance imaging in systemic sclerosis: a cross-sectional observational study of 52 patients. Ann Rheum Dis 68:1878–1884PubMedCentralPubMedCrossRef

28.

Joven BE, Almodovar R, Carmona L, Carreira PE (2010) Survival, causes of death, and risk factors associated with mortality in Spanish systemic sclerosis patients: results from a single university hospital. Semin Arthritis Rheum 39:285–293PubMedCrossRef

29.

Maione S, Cuomo G, Giunta A, Tanturri de Horatio L, La Montagna G, Manguso F, Alagia I, Valentini G (2005) Echocardiographic alterations in systemic sclerosis: a longitudinal study. Semin Arthritis Rheum 34:721–727PubMedCrossRef

30.

Minier T, Pentek M, Brodszky V, Ecseki A, Kárpáti K, Polgár A, Czirják L, Gulácsi L (2010) Cost-of-illness of patients with systemic sclerosis in a tertiary care centre. Rheumatology (Oxford) 49:1920–1928CrossRef

31.

Mok MY, Fung PC, Ooi C, Tse HF, Wong Y, Lam YM, Wong WS, Lau CS (2008) Serum nitric oxide metabolites and disease activity in patients with systemic sclerosis. Clin Rheumatol 27:315–322PubMedCrossRef

32.

Muller H, Rehberger P, Gunther C, Schmitt J (2012) Determinants of disability, quality of life and depression in dermatological patients with systemic scleroderma. Br J Dermatol 166:343–353PubMedCrossRef

33.

Nietert PJ, Mitchell HC, Bolster MB, Curran MY, Tilley BC, Silver RM (2005) Correlates of depression, including overall and gastrointestinal functional status, among patients with systemic sclerosis. J Rheumatol 32:51–57PubMed

34.

Schmajuk G, Bush TM, Burkham J, Krishnan E, Chung L (2009) Characterizing systemic sclerosis in Northern California: focus on Asian and Hispanic patients. Clin Exp Rheumatol 27(Suppl 54):22–25PubMed

35.

Teh CL, Kuan YC, Wong JS (2009) Systemic sclerosis in Sarawak: a profile of patients treated in the Sarawak General Hospital. Rheumatol Int 29:1243–1245PubMedCrossRef

36.

Yiu KH, Schouffoer AA, Marsan NA, Ninaber MK, Stolk J, Vlieland TV, Scherptong RW, Delgado V, Holman ER, Tse HF, Huizinga TW, Bax JJ, Schuerwegh AJ (2011) Left ventricular dysfunction assessed by speckle-tracking strain analysis in patients with systemic sclerosis: relationship to functional capacity and ventricular arrhythmias. Arthritis Rheum 63:3969–3978PubMedCrossRef

37.

Araujo FG, Amaral TN, Appenzeller S, de Carvalho JF (2013) Seizures in systemic sclerosis. Rheumatol Int 33:1721–1724PubMedCrossRef

38.

Marino Claverie L, Knobel E, Takashima L, Techera L, Oliver M, Gonzalez P, Romanini FE, Fonseca ML, Mamani MN (2013) Organ involvement in Argentinian systemic sclerosis patients with “late” pattern as compared to patients with “early/active” pattern by nailfold capillaroscopy. Clin Rheumatol 32:839–843PubMedCrossRef

39.

Hinchcliff M, Desai CS, Varga J, Shah SJ (2012) Prevalence, prognosis, and factors associated with left ventricular diastolic dysfunction in systemic sclerosis. Clin Exp Rheumatol 30(Suppl 71):S30–S37PubMedCentralPubMed

40.

Rodriguez-Reyna TS, Hinojosa-Azaola A, Martinez-Reyes C, Nuñez-Alvarez CA, Torrico-Lavayen R, García-Hernández JL, Cabiedes-Contreras J (2011) Distinctive autoantibody profile in Mexican Mestizo systemic sclerosis patients. Autoimmunity 44:576–584PubMedCrossRef

41.

Steen VD, Lanz JK Jr, Conte C, Owens GR, Medsger TA Jr (1994) Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study. Arthritis Rheum 37:1290–1296PubMedCrossRef

42.

Behr J, Vogelmeier C, Beinert T, Meurer M, Krombach F, Konig G, Fruhmann G (1996) Bronchoalveolar lavage for evaluation and management of scleroderma disease of the lung. Am J Respir Crit Care Med 154:400–406PubMedCrossRef

43.

Ranque B, Authier FJ, Le-Guern V, Pagnoux C, Berezne A, Allanore Y, Launay D, Hachulla E, Kahan A, Cabane J, Gherardi R, Guillevin L, Mouthon L (2009) A descriptive and prognostic study of systemic sclerosis-associated myopathies. Ann Rheum Dis 68:1474–1477PubMedCrossRef

44.

Calguneri M, Apras S, Ozbalkan Z, Ertenli I, Kiraz S, Ozturk MA, Celik I (2003) The efficacy of oral cyclophosphamide plus prednisolone in early diffuse systemic sclerosis. Clin Rheumatol 22:289–294PubMedCrossRef

45.

Apras S, Ertenli I, Ozbalkan Z, Kiraz S, Ozturk MA, Haznedaroglu IC, Cobankara V, Pay S, Calguneri M (2003) Effects of oral cyclophosphamide and prednisolone therapy on the endothelial functions and clinical findings in patients with early diffuse systemic sclerosis. Arthritis Rheum 48:2256–2261PubMedCrossRef

46.

Valentini G, Paone C, La Montagna G, Chiarolanza I, Menegozzo M, Colutta E, Ruocco L (2006) Low-dose intravenous cyclophosphamide in systemic sclerosis: an open prospective efficacy study in patients with early diffuse disease. Scand J Rheumatol 35:35–38PubMedCrossRef

47.

Vanthuyne M, Blockmans D, Westhovens R, Roufosse F, Cogan E, Coche E, Nzeusseu Toukap A, Depresseux G, Houssiau FA (2007) A pilot study of mycophenolate mofetil combined to intravenous methylprednisolone pulses and oral low-dose glucocorticoids in severe early systemic sclerosis. Clin Exp Rheumatol 25:287–292PubMed

48.

Nadashkevich O, Davis P, Fritzler M, Kovalenko W (2006) A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis. Clin Rheumatol 25:205–212PubMedCrossRef

49.

Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS, Roberts C, Desai S, Herrick AL, McHugh NJ, Foley NM, Pearson SB, Emery P, Veale DJ, Denton CP, Wells AU, Black CM, du Bois RM (2006) A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 54:3962–3970PubMedCrossRef

50.

Davas EM, Peppas C, Maragou M, Alvanou E, Hondros D, Dantis PC (1999) Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with scleroderma. Clin Rheumatol 18:455–461PubMedCrossRef

51.

Beretta L, Caronni M, Raimondi M, Ponti A, Viscuso T, Origgi L, Scorza R (2007) Oral cyclophosphamide improves pulmonary function in scleroderma patients with fibrosing alveolitis: experience in one centre. Clin Rheumatol 26:168–172PubMedCrossRef

52.

Giacomelli R, Valentini G, Salsano F, Cipriani P, Sambo P, Conforti ML, Fulminis A, De Luca A, Farina G, Candela M, Generini S, De Francisci A, Tirri E, Proietti M, Bombardieri S, Gabrielli A, Tonietti G, Cerinic MM (2002) Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. J Rheumatol 29:731–736PubMed

53.

Akesson A, Scheja A, Lundin A, Wollheim FA (1994) Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide. Arthritis Rheum 37:729–735PubMedCrossRef

54.

Silver RM, Warrick JH, Kinsella MB, Staudt LS, Baumann MH, Strange C (1993) Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol 20:838–844PubMed

55.

Liossis SN, Bounas A, Andonopoulos AP (2006) Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease. Rheumatology (Oxford) 45:1005–1008CrossRef

56.

Wanchu A, Suryanaryana BS, Sharma S, Sharma A, Bambery P (2009) High-dose prednisolone and bolus cyclophosphamide in interstitial lung disease associated with systemic sclerosis: a prospective open study. Int J Rheum Dis 12:239–242PubMedCrossRef

57.

Tochimoto A, Kawaguchi Y, Hara M, Tateishi M, Fukasawa C, Takagi K, Nishimagi E, Ota Y, Katsumata Y, Gono T, Tanaka E, Yamanaka H (2011) Efficacy and safety of intravenous cyclophosphamide pulse therapy with oral prednisolone in the treatment of interstitial lung disease with systemic sclerosis: 4-year follow-up. Mod Rheumatol 21:296–301PubMed

58.

Griffiths B, Miles S, Moss H, Robertson R, Veale D, Emery P (2002) Systemic sclerosis and interstitial lung disease: a pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function. J Rheumatol 29:2371–2378PubMed

59.

Airo P, Danieli E, Rossi M, Frassi M, Cavazzana I, Scarsi M, Grottolo A, Franceschini F, Zambruni A (2007) Intravenous cyclophosphamide for interstitial lung disease associated to systemic sclerosis: results with an 18-month long protocol including a maintenance phase. Clin Exp Rheumatol 25:293–296PubMed

60.

Yiannopoulos G, Pastromas V, Antonopoulos I, Katsiberis G, Kalliolias G, Liossis SN, Andonopoulos AP (2007) Combination of intravenous pulses of cyclophosphamide and methylprednizolone in patients with systemic sclerosis and interstitial lung disease. Rheumatol Int 27:357–361PubMedCrossRef

61.

Simeon-Aznar CP, Fonollosa-Pla V, Tolosa-Vilella C, Selva-O Callaghan A, Solans-Laque R, Palliza E, Munoz X, Vilardell-Tarrés M (2008) Intravenous cyclophosphamide pulse therapy in the treatment of systemic sclerosis-related interstitial lung disease: a long term study. Open Respir Med J 2:39–45PubMedCentralPubMedCrossRef

62.

Harding S, Khimdas S, Bonner A, Baron M, Pope J, Canadian Scleroderma Research Group (2012) Best practices in scleroderma: an analysis of practice variability in SSc centres within the Canadian Scleroderma Research Group (CSRG). Clin Exp Rheumatol 30(2 Suppl 71):S38–43PubMed

63.

Delany AM, Brinckerhoff CE (1992) Post-transcriptional regulation of collagenase and stromelysin gene expression by epidermal growth factor and dexamethasone in cultured human fibroblasts. J Cell Biochem 50:400–410PubMedCrossRef

64.

Kowal-Bielecka O, Landewe R, Avouac J, Chwiesko S, Miniati I, Czirjak L, Clements P, Denton C, Farge D, Fligelstone K, Földvari I, Furst DE, Müller-Ladner U, Seibold J, Silver RM, Takehara K, Toth BG, Tyndall A, Valentini G, van den Hoogen F, Wigley F, Zulian F, Matucci-Cerinic M, EUSTAR Co-Authors (2009) EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 68:620–628PubMedCrossRef

Title: Prevalence and factors associated with glucocorticoids (GC) use in systemic sclerosis (SSc): a systematic review and meta-analysis of cohort studies and registries
Authors: Michele Iudici
Serena Fasano
Daniela Iacono
Barbara Russo
Giovanna Cuomo
Gabriele Valentini
Publication date: 01-02-2014
Publisher: Springer London
Published in: Clinical Rheumatology / Issue 2/2014
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-013-2422-0

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Prevalence and factors associated with glucocorticoids (GC) use in systemic sclerosis (SSc): a systematic review and meta-analysis of cohort studies and registries

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2014

Serum galectin-3 level in systemic sclerosis

Impact of cardiac involvement on the risk of mortality among patients with systemic sclerosis: a 5-year follow-up of a single-center cohort

Occupational exposure in patients with the antisynthetase syndrome

Refractory hemophagocytic syndrome in systemic lupus erythematosus successfully treated with intermittent intravenous cyclophosphamide: three case reports and literature review

Prevalence of psoriatic arthritis in psoriasis patients according to newer classification criteria

Successful treatment of refractory aortitis in antineutrophil cytoplasmic antibody-associated vasculitis using tocilizumab

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page